| Year |
Citation |
Score |
| 2022 |
Watts EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, Noor U, Andrews CD, Gunter MJ, Holmes MV, Martin RM, Tsilidis KK, Albanes D, Barricarte A, Bueno-de-Mesquita HB, Cohn BA, Deschasaux-Tanguy M, ... ... Pollak MN, et al. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. International Journal of Epidemiology. PMID 35726641 DOI: 10.1093/ije/dyac124 |
0.336 |
|
| 2022 |
Ma C, Wang Y, Wilson KM, Mucci LA, Stampfer MJ, Pollak M, Penney KL. Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer. Jnci Cancer Spectrum. 6: pkab091. PMID 35047751 DOI: 10.1093/jncics/pkab091 |
0.339 |
|
| 2021 |
Rosendahl AH, Björner S, Ygland Rödström M, Jirström K, Borgquist S, Ingvar C, Pollak MN, Jernström H. Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control Study. Frontiers in Oncology. 11: 626058. PMID 33767994 DOI: 10.3389/fonc.2021.626058 |
0.33 |
|
| 2020 |
Gómez-Izquierdo J, Filion KB, Boivin JF, Azoulay L, Pollak M, Yu OHY. Subclinical hypothyroidism and the risk of cancer incidence and cancer mortality: a systematic review. Bmc Endocrine Disorders. 20: 83. PMID 32517676 DOI: 10.1186/S12902-020-00566-9 |
0.349 |
|
| 2020 |
Meyerhardt JA, Irwin ML, Jones LW, Zhang S, Campbell N, Brown JC, Pollak M, Sorrentino A, Cartmel B, Harrigan M, Tolaney SM, Winer E, Ng K, Abrams T, Fuchs CS, et al. Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. Jnci Cancer Spectrum. 4: pkz096. PMID 32090192 DOI: 10.1093/Jncics/Pkz096 |
0.33 |
|
| 2019 |
Hada M, Oh H, Pfeiffer RM, Falk RT, Fan S, Mullooly M, Pollak M, Geller B, Vacek PM, Weaver D, Shepherd J, Wang J, Fan B, Mahmoudzadeh AP, Malkov S, et al. Relationship of circulating insulin-like growth factor-I and binding proteins 1-7 with mammographic density among women undergoing image-guided diagnostic breast biopsy. Breast Cancer Research : Bcr. 21: 81. PMID 31337427 DOI: 10.1186/S13058-019-1162-8 |
0.434 |
|
| 2019 |
Watts EL, Perez-Cornago A, Appleby PN, Albanes D, Ardanaz E, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chubb SAP, Cook MB, Deschasaux M, Donovan JL, English DR, Flicker L, ... ... Pollak M, et al. The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies. International Journal of Cancer. PMID 30873591 DOI: 10.1002/Ijc.32276 |
0.408 |
|
| 2019 |
Heitzeneder S, Sotillo E, Shern JF, Sindiri S, Xu P, Jones R, Pollak M, Noer PR, Lorette J, Fazli L, Alag A, Meltzer P, Lau C, Conover CA, Oxvig C, et al. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. Journal of the National Cancer Institute. PMID 30698726 DOI: 10.1093/Jnci/Djy209 |
0.317 |
|
| 2019 |
Mark M, Klingbiel D, Mey U, Winterhalder R, Rothermundt C, Gillessen S, von Moos R, Pollak M, Manetsch G, Strebel R, Cathomas R. Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. Clinical Genitourinary Cancer. PMID 30686756 DOI: 10.1016/J.Clgc.2018.12.009 |
0.349 |
|
| 2019 |
Campbell PT, Newton C, Jacobs EJ, Pollak M, Gapstur SM. Abstract 594: Associations of hemoglobin A1c with risk of diabetes-related cancers in the Cancer Prevention Study-II Nutrition Cohort (CPS-II NC) Epidemiology. DOI: 10.1158/1538-7445.Sabcs18-594 |
0.335 |
|
| 2019 |
Guinter M, Gapstur S, Flanders WD, Wang Y, Rees-Punia E, McCullough M, Alcaraz KI, Pollak M, Campbell P. Abstract 596: Association between an empirically-derived inflammatory lifestyle score and incident colorectal cancer Cancer Research. 79: 596-596. DOI: 10.1158/1538-7445.Am2019-596 |
0.354 |
|
| 2019 |
Wang Y, Campbell PT, Stevens VL, Newton CC, Jacobs EJ, Pollak M, Gapstur SM. Abstract 2683: Biomarkers of glucose homeostasis and inflammation and risk of prostate cancer: A case-cohort study Cancer Research. 79: 2683-2683. DOI: 10.1158/1538-7445.Am2019-2683 |
0.371 |
|
| 2018 |
Lord SR, Cheng WC, Liu D, Gaude E, Haider S, Metcalf T, Patel N, Teoh EJ, Gleeson F, Bradley K, Wigfield S, Zois C, McGowan DR, Ah-See ML, Thompson AM, ... ... Pollak M, et al. Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. Cell Metabolism. PMID 30244975 DOI: 10.1016/J.Cmet.2018.08.021 |
0.322 |
|
| 2018 |
Hulea L, Gravel SP, Morita M, Cargnello M, Uchenunu O, Im YK, Lehuédé C, Ma EH, Leibovitch M, McLaughlan S, Blouin MJ, Parisotto M, Papavasiliou V, Lavoie C, Larsson O, ... ... Pollak M, et al. Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. Cell Metabolism. PMID 30244971 DOI: 10.1016/J.Cmet.2018.09.001 |
0.338 |
|
| 2018 |
Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou K, Graff RE, Sinnott JA, Fazli L, Judson GL, Bismar TA, Rider JR, Gerke T, Chan JM, Fiorentino M, Flavin R, ... ... Pollak M, et al. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis. PMID 30165429 DOI: 10.1093/Carcin/Bgy112 |
0.437 |
|
| 2018 |
Pollak M. Diet boosts the effectiveness of a cancer drug. Nature. 560: 439-440. PMID 30127476 DOI: 10.1038/D41586-018-05871-X |
0.402 |
|
| 2018 |
Im YK, Najyb O, Gravel SP, McGuirk S, Ahn R, Avizonis D, Chénard V, Sabourin V, Hudson J, Pawson T, Topisirovic I, Pollak MN, St-Pierre J, Ursini-Siegel J. Interplay between ShcA signaling and PGC-1α triggers targetable metabolic vulnerabilities in breast cancer. Cancer Research. PMID 29930100 DOI: 10.1158/0008-5472.Can-17-3696 |
0.337 |
|
| 2018 |
Tognon CE, Rafn B, Cetinbas NM, Kamura T, Trigo G, Rotblat B, Okumura F, Matsumoto M, Chow C, Davare M, Pollak M, Mayor T, Sorensen PH. Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation. The Journal of Biological Chemistry. PMID 29903916 DOI: 10.1074/Jbc.Ra117.000321 |
0.391 |
|
| 2018 |
Oh H, Pfeiffer RM, Falk RT, Horne HN, Xiang J, Pollak M, Brinton LA, Storniolo AMV, Sherman ME, Gierach GL, Figueroa JD. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: the Susan G. Komen Tissue Bank. International Journal of Cancer. PMID 29473153 DOI: 10.1002/Ijc.31333 |
0.391 |
|
| 2018 |
Oh H, Pfeiffer RM, Falk RT, Horne HN, Xiang J, Pollak M, Brinton LA, Storniolo AMV, Sherman ME, Gierach GL, Figueroa JD. Abstract A36: Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution in Caucasian and African American women: The Susan G. Komen Tissue Bank Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-A36 |
0.425 |
|
| 2018 |
Mahalingam D, Hanni S, Fountzilas C, Michalek J, Sarantopoulos J, Pillai SMA, Kuhn J, Pollak M, Thompson I. Abstract 3269: Metformin to prevent metabolic syndrome associated with androgen deprivation therapy (ADT): Metabolic analysis from a placebo-controlled study of metformin in non-diabetic men initiating ADT for advanced prostate cancer (PCa) Cancer Research. 78: 3269-3269. DOI: 10.1158/1538-7445.Am2018-3269 |
0.381 |
|
| 2017 |
Aneke-Nash CS, Xue X, Qi Q, Biggs ML, Cappola A, Kuller L, Pollak M, Psaty BM, Siscovick D, Mukamal K, Strickler HD, Kaplan RC. The Association between IGF-I and IGFBP-3 and Incident Diabetes in an Older Population of Men and Women in the Cardiovascular Health Study. The Journal of Clinical Endocrinology and Metabolism. PMID 29040592 DOI: 10.1210/Jc.2017-01273 |
0.371 |
|
| 2017 |
Wu JW, Azoulay L, Majdan A, Boivin JF, Pollak M, Suissa S. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017734491. PMID 28953430 DOI: 10.1200/Jco.2017.73.4491 |
0.4 |
|
| 2017 |
Toriola AT, Ziegler M, Li Y, Pollak M, Stolzenberg-Solomon R. Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival. Annals of Surgical Oncology. PMID 28681154 DOI: 10.1245/S10434-017-5988-Y |
0.43 |
|
| 2017 |
Gucalp A, Iyengar NM, Zhou XK, Giri DD, Falcone DJ, Wang H, Williams S, Krasne MD, Yaghnam I, Kunzel B, Morris PG, Jones LW, Pollak M, Laudone VP, Hudis CA, et al. Periprostatic adipose inflammation is associated with high-grade prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 28653675 DOI: 10.1038/Pcan.2017.31 |
0.318 |
|
| 2017 |
Lin D, Ettinger SL, Qu S, Xue H, Nabavi N, Choi SYC, Bell RH, Mo F, Haegert AM, Gout PW, Fleshner N, Gleave ME, Pollak M, Collins CC, Wang Y. Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. Oncotarget. 8: 25928-25941. PMID 28460430 DOI: 10.18632/Oncotarget.15237 |
0.355 |
|
| 2017 |
Miles FL, Goodman PJ, Tangen C, Torkko KC, Schenk JM, Song X, Pollak M, Thompson IM, Neuhouser ML. Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients. 9. PMID 28417914 DOI: 10.3390/Nu9040378 |
0.414 |
|
| 2017 |
Brown KA, Iyengar NM, Zhou XK, Gucalp A, Subbaramaiah K, Wang H, Giri DD, Morrow M, Falcone DJ, Wendel NK, Winston LA, Pollak M, Dierickx A, Hudis CA, Dannenberg AJ. Menopause is a determinant of breast aromatase expression and its associations with BMI, inflammation and systemic markers. The Journal of Clinical Endocrinology and Metabolism. PMID 28323914 DOI: 10.1210/Jc.2016-3606 |
0.324 |
|
| 2017 |
Iyengar NM, Brown KA, Zhou XK, Gucalp A, Subbaramaiah K, Giri DD, Zahid H, Bhardwaj P, Wendel NK, Falcone DJ, Wang H, Williams S, Pollak M, Morrow M, Hudis CA, et al. Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. Cancer Prevention Research (Philadelphia, Pa.). PMID 28270386 DOI: 10.1158/1940-6207.Capr-16-0314 |
0.327 |
|
| 2017 |
Hulea L, Cargnello M, Gravel S, Im Y, McLaughlan S, Zhao Y, Ching J, Cai Y, Larsson O, Ohh M, Ursini-Siegel J, St-Pierre J, Pollak M, Topisirovic I. Abstract A31: eIF4F links translation to energy stress response in cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Transcontrol16-A31 |
0.367 |
|
| 2017 |
Iyengar N, Brown K, Zhou X, Subbaramaiah K, Giri D, Gucalp A, Howe L, Zahid H, Bhardwaj P, Wendel N, Falcone D, Morrow M, Wang H, Williams S, Pollak M, et al. Abstract PD5-05: Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd5-05 |
0.345 |
|
| 2017 |
Choi SY, Ettinger SL, Lin D, Xue H, Bell RH, Mo F, Pollak M, Collins CC, Wang Y. Abstract 4420: Elevated glycolytic gene signature in patient-derived neuroendocrine prostate cancer xenograft models and its clinical relevance Cancer Research. 77: 4420-4420. DOI: 10.1158/1538-7445.Am2017-4420 |
0.335 |
|
| 2016 |
Murphy N, Falk RT, Messinger DB, Pollak M, Xue X, Lin J, Sgueglia R, Strickler HD, Gaudet MM, Gunter MJ. Influence of Fasting Status and Sample Preparation on Metabolic Biomarker Measurements in Postmenopausal Women. Plos One. 11: e0167832. PMID 27930694 DOI: 10.1371/Journal.Pone.0167832 |
0.381 |
|
| 2016 |
Kaplan RC, Strizich G, Aneke-Nash C, Dominguez-Islas C, Bůžková P, Strickler H, Rohan T, Pollak M, Kuller L, Kizer JR, Cappola A, Li CI, Psaty BM, Newman A. Insulinlike growth factor binding protein-1 and ghrelin predict health outcomes among older adults: CHS cohort. The Journal of Clinical Endocrinology and Metabolism. jc20162779. PMID 27820656 DOI: 10.1210/Jc.2016-2779 |
0.313 |
|
| 2016 |
Gusscott S, Jenkins CE, Lam SH, Giambra V, Pollak M, Weng AP. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. Plos One. 11: e0161158. PMID 27532210 DOI: 10.1371/Journal.Pone.0161158 |
0.361 |
|
| 2016 |
Hayes BD, Brady L, Pollak MN, Finn S. Exercise and prostate cancer: evidence and proposed mechanisms for disease modification. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27389872 DOI: 10.1158/1055-9965.Epi-16-0223 |
0.363 |
|
| 2016 |
Teumer A, Qi Q, Nethander M, Aschard H, Bandinelli S, Beekman M, Berndt SI, Bidlingmaier M, Broer L, Cappola A, Ceda GP, Chanock S, Chen MH, Chen TC, ... ... Pollak MN, et al. Genomewide meta-analysis identifies loci associated with IGF-I and IGFBP-3 levels with impact on age-related traits. Aging Cell. PMID 27329260 DOI: 10.1111/Acel.12490 |
0.614 |
|
| 2016 |
Yancu D, Blouin MJ, Birman E, Florianova L, Aleynikova O, Zakikhani M, VanderMeulen H, Seidman E, Pollak M. Insulin-like growth factor-3 knockout mice are resistant to experimental dextran sulfate sodium colitis. Journal of Gastroenterology and Hepatology. PMID 27253188 DOI: 10.1111/Jgh.13461 |
0.379 |
|
| 2016 |
Liu Z, Yokoyama NN, Blair CA, Li X, Avizonis D, Wu XR, Uchio E, Youssef R, McClelland M, Pollak M, Zi X. High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum. Molecular Cancer Therapeutics. PMID 26921394 DOI: 10.1158/1535-7163.Mct-15-0714-T |
0.376 |
|
| 2016 |
Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, ... ... Pollak MN, et al. A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Research. 76: 2288-300. PMID 26921328 DOI: 10.1158/0008-5472.Can-15-1551 |
0.43 |
|
| 2016 |
Horne HN, Sherman ME, Pfeiffer RM, Figueroa JD, Khodr ZG, Falk RT, Pollak M, Patel DA, Palakal MM, Linville L, Papathomas D, Geller B, Vacek PM, Weaver DL, Chicoine R, et al. Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. Breast Cancer Research : Bcr. 18: 24. PMID 26893016 DOI: 10.1186/S13058-016-0678-4 |
0.404 |
|
| 2016 |
Aneke-Nash CS, Dominguez-Islas C, Bůžková P, Qi Q, Xue X, Pollak M, Strickler HD, Kaplan RC. Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies. Growth Hormone & Igf Research : Official Journal of the Growth Hormone Research Society and the International Igf Research Society. 26: 11-6. PMID 26774400 DOI: 10.1016/J.Ghir.2015.12.007 |
0.355 |
|
| 2016 |
Sgroi DC, Chapman JA, Badovinac-Crnjevic T, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Goss PE, Pollak M. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. Breast Cancer Research : Bcr. 18: 1. PMID 26728744 DOI: 10.1186/S13058-015-0660-6 |
0.362 |
|
| 2015 |
Iyengar NM, Zhou XK, Gucalp A, Morris PG, Howe LR, Giri D, Morrow M, Wang H, Pollak M, Jones LW, Hudis CA, Dannenberg AJ. Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26712688 DOI: 10.1158/1078-0432.Ccr-15-2239 |
0.375 |
|
| 2015 |
Azoulay L, Eberg M, Benayoun S, Pollak M. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. Jama Oncology. 1: 314-20. PMID 26181177 DOI: 10.1001/Jamaoncol.2015.0387 |
0.353 |
|
| 2015 |
Catsburg C, Gunter MJ, Tinker L, Chlebowski RT, Pollak M, Strickler HD, Cote ML, Page DL, Rohan TE. Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. Journal of Cancer Epidemiology. 2015: 203284. PMID 26106415 DOI: 10.1155/2015/203284 |
0.363 |
|
| 2015 |
Stolzenberg-Solomon RZ, Newton CC, Silverman DT, Pollak M, Nogueira LM, Weinstein SJ, Albanes D, Männistö S, Jacobs EJ. Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts. American Journal of Epidemiology. PMID 26085045 DOI: 10.1093/Aje/Kwv041 |
0.41 |
|
| 2015 |
Joerger M, van Schaik RH, Becker ML, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen S, Rothermundt C. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer and Prostatic Diseases. 18: 167-72. PMID 25753371 DOI: 10.1038/Pcan.2015.8 |
0.318 |
|
| 2015 |
Blouin MJ, Bazile M, Birman E, Zakikhani M, Florianova L, Aleynikova O, Powell DR, Pollak M. Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia. Breast Cancer Research and Treatment. 149: 577-85. PMID 25614235 DOI: 10.1007/S10549-015-3268-8 |
0.376 |
|
| 2015 |
Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, Pollak MN, Kenfield SA, Stampfer MJ, Giovannucci EL. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. International Journal of Cancer. Journal International Du Cancer. 136: 2418-26. PMID 25348852 DOI: 10.1002/Ijc.29295 |
0.323 |
|
| 2015 |
Zell JA, McLaren CE, Morgan TR, Lawson MJ, Rezk S, Albers GC, Chen W, Carmichael JC, Rodriguez L, Szabo E, Ford L, Pollak M, Meyskens FL. Abstract A21: A Phase IIa trial of metformin for colorectal cancer risk reduction among patients with a history of colorectal adenomas and elevated body mass index Cancer Prevention Research. 8. DOI: 10.1158/1940-6215.Prev-14-A21 |
0.331 |
|
| 2015 |
Iyengar NM, Gucalp A, Zhou XK, Howe LR, Morris PG, Giri D, Subbaramaiah K, Bhardwaj P, Park SS, Pollak M, Morrow M, Hudis CA, Dannenberg AJ. Abstract P4-04-12: Both metabolic syndrome and statin use are more common in women with breast inflammation Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-04-12 |
0.364 |
|
| 2014 |
Gravel SP, Hulea L, Toban N, Birman E, Blouin MJ, Zakikhani M, Zhao Y, Topisirovic I, St-Pierre J, Pollak M. Serine deprivation enhances antineoplastic activity of biguanides. Cancer Research. 74: 7521-33. PMID 25377470 DOI: 10.1158/0008-5472.Can-14-2643-T |
0.334 |
|
| 2014 |
Paxton RJ, Jung SY, Vitolins MZ, Fenton J, Paskett E, Pollak M, Hays-Grudo J, Hursting SD, Chang S. Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers. Cancer Causes & Control : Ccc. 25: 1427-37. PMID 25238978 DOI: 10.1007/S10552-014-0434-Y |
0.366 |
|
| 2014 |
Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, Gotlieb WH. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecologic Oncology. 134: 607-14. PMID 24972190 DOI: 10.1016/J.Ygyno.2014.06.014 |
0.369 |
|
| 2014 |
Jacobs EJ, Newton CC, Silverman DT, Nogueira LM, Albanes D, Männistö S, Pollak M, Stolzenberg-Solomon RZ. Serum transforming growth factor-β1 and risk of pancreatic cancer in three prospective cohort studies. Cancer Causes & Control : Ccc. 25: 1083-91. PMID 24913781 DOI: 10.1007/S10552-014-0409-Z |
0.337 |
|
| 2014 |
Beasley JM, Wedick NM, Rajpathak SN, Xue X, Holmes MD, Gunter MJ, Wylie-Rosett J, Rohan TE, Pollak M, Kaplan RC, Hu FB, Sun Q, Strickler HD. Circulating IGF-axis protein levels and their relation with levels of plasma adipocytokines and macronutrient consumption in women. Growth Hormone & Igf Research : Official Journal of the Growth Hormone Research Society and the International Igf Research Society. 24: 142-9. PMID 24888819 DOI: 10.1016/J.Ghir.2014.04.006 |
0.357 |
|
| 2014 |
Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M, Schwab M, Hofmann U, Evans A, van der Kwast T, Trachtenberg J, Finelli A, Fleshner N, Sweet J, Pollak M. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer and Prostatic Diseases. 17: 252-8. PMID 24861559 DOI: 10.1038/Pcan.2014.20 |
0.395 |
|
| 2014 |
Cao Y, Lindström S, Schumacher F, Stevens VL, Albanes D, Berndt S, Boeing H, Bueno-de-Mesquita HB, Canzian F, Chamosa S, Chanock SJ, Diver WR, Gapstur SM, Gaziano JM, Giovannucci EL, ... ... Pollak M, et al. Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. Journal of the National Cancer Institute. 106: dju085. PMID 24824313 DOI: 10.1093/Jnci/Dju218 |
0.437 |
|
| 2014 |
Takeuchi A, Shiota M, Beraldi E, Thaper D, Takahara K, Ibuki N, Pollak M, Cox ME, Naito S, Gleave ME, Zoubeidi A. Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. Molecular and Cellular Endocrinology. 384: 117-25. PMID 24491388 DOI: 10.1016/J.Mce.2014.01.012 |
0.425 |
|
| 2014 |
Mireuta M, Birman E, Barmash M, Pollak M. Quantification of binding of IGF-1 to BI 836845, a candidate therapeutic antibody against IGF-1 and IGF-2, and effects of this antibody on IGF-1:IGFBP-3 complexes in vitro and in male C57BL/6 mice. Endocrinology. 155: 703-15. PMID 24424057 DOI: 10.1210/En.2013-1791 |
0.353 |
|
| 2014 |
Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff JH, Cathomas R, Gillessen S. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). European Urology. 66: 468-74. PMID 24412228 DOI: 10.1016/J.Eururo.2013.12.057 |
0.337 |
|
| 2014 |
Grimaldi-Bensouda L, Cameron D, Marty M, Barnett AH, Penault-Llorca F, Pollak M, Charbonnel B, Riddle M, Mignot L, Boivin JF, Khachatryan A, Rossignol M, Bénichou J, Alpérovitch A, Abenhaim L, et al. Risk of breast cancer by individual insulin use: an international multicenter study. Diabetes Care. 37: 134-43. PMID 23949559 DOI: 10.2337/Dc13-0695 |
0.409 |
|
| 2014 |
Pollak M. Energy balance at the organism and cellular level: effects of biguanides Cancer & Metabolism. 2. DOI: 10.1186/2049-3002-2-S1-O26 |
0.385 |
|
| 2013 |
Muhlbradt E, Ma J, Severi G, Ortner E, Hayes V, Hoang HN, Stampfer M, Giles G, Pollak M, Gelmann EP. Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. Genes & Cancer. 4: 535-45. PMID 24386513 DOI: 10.1177/1947601913506009 |
0.384 |
|
| 2013 |
Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. Journal of the National Cancer Institute. 105: 1881-90. PMID 24292212 DOI: 10.1093/Jnci/Djt332 |
0.409 |
|
| 2013 |
Van Dang C, Pollak M. Why Cancer & Metabolism? Why now? Cancer & Metabolism. 1: 1. PMID 24280107 DOI: 10.1186/2049-3002-1-1 |
0.352 |
|
| 2013 |
Hvid H, Blouin MJ, Birman E, Damgaard J, Poulsen F, Fels JJ, Fledelius C, Hansen BF, Pollak M. Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts. Plos One. 8: e79710. PMID 24260289 DOI: 10.1371/Journal.Pone.0079710 |
0.421 |
|
| 2013 |
Pollak M. Potential applications for biguanides in oncology. The Journal of Clinical Investigation. 123: 3693-700. PMID 23999444 DOI: 10.1172/Jci67232 |
0.301 |
|
| 2013 |
Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, et al. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 1984-93. PMID 23983239 DOI: 10.1158/1055-9965.Epi-13-0349 |
0.322 |
|
| 2013 |
Takahara K, Ibuki N, Ghaffari M, Tearle H, Ong CJ, Azuma H, Gleave ME, Pollak M, Cox ME. The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice Prostate Cancer and Prostatic Diseases. 16: 239-247. PMID 23689346 DOI: 10.1038/Pcan.2013.14 |
0.39 |
|
| 2013 |
Palumbo MO, Kavan P, Miller WH, Panasci L, Assouline S, Johnson N, Cohen V, Patenaude F, Pollak M, Jagoe RT, Batist G. Systemic cancer therapy: achievements and challenges that lie ahead. Frontiers in Pharmacology. 4: 57. PMID 23675348 DOI: 10.3389/Fphar.2013.00057 |
0.322 |
|
| 2013 |
Lubik AA, Gunter JH, Hollier BG, Ettinger S, Fazli L, Stylianou N, Hendy SC, Adomat HH, Gleave ME, Pollak M, Herington A, Nelson CC. IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocrine-Related Cancer. 20: 173-86. PMID 23319492 DOI: 10.1530/Erc-12-0250 |
0.42 |
|
| 2013 |
Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prevention Research (Philadelphia, Pa.). 6: 91-9. PMID 23315596 DOI: 10.1158/1940-6207.Capr-12-0250 |
0.44 |
|
| 2013 |
Song Y, Chavarro JE, Cao Y, Qiu W, Mucci L, Sesso HD, Stampfer MJ, Giovannucci E, Pollak M, Liu S, Ma J. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. The Journal of Nutrition. 143: 189-96. PMID 23256145 DOI: 10.3945/Jn.112.168484 |
0.316 |
|
| 2013 |
Dallal CM, Brinton LA, Bauer DC, Buist DS, Cauley JA, Hue TF, Lacroix A, Tice JA, Chia VM, Falk R, Pfeiffer R, Pollak M, Veenstra TD, Xu X, Lacey JV, et al. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. Endocrine-Related Cancer. 20: 151-60. PMID 23222000 DOI: 10.1530/Erc-12-0229 |
0.373 |
|
| 2013 |
Liao LM, Weinstein SJ, Pollak M, Li Z, Virtamo J, Albanes D, Chow WH, Purdue MP. Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. Carcinogenesis. 34: 109-12. PMID 23042303 DOI: 10.1093/Carcin/Bgs322 |
0.33 |
|
| 2013 |
Jung SY, Hays-Grudo J, Paskett E, Hursting SD, Fenton J, Pollak M, Vitolins M, Chang S. Abstract PR04: Exogenous estrogen as a mediator of racial differences in insulin-like growth factor-I levels among postmenopausal women Cancer Prevention Research. 6. DOI: 10.1158/1940-6215.Prev-13-Pr04 |
0.35 |
|
| 2013 |
Jung SY, Paxton RJ, Hays-Grudo J, Paskett E, Hursting SD, Fenton J, Pollak M, Vitolins M, Chang S. Abstract A35: Associations between time spent sitting and cancer-related biomarkers: An exploration of effect modifiers Cancer Prevention Research. 6. DOI: 10.1158/1940-6215.Prev-13-A35 |
0.359 |
|
| 2012 |
Evdokimova V, Tognon CE, Benatar T, Yang W, Krutikov K, Pollak M, Sorensen PH, Seth A. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Science Signaling. 5: ra92. PMID 23250396 DOI: 10.1126/Scisignal.2003184 |
0.412 |
|
| 2012 |
Birmann BM, Neuhouser ML, Rosner B, Albanes D, Buring JE, Giles GG, Lan Q, Lee IM, Purdue MP, Rothman N, Severi G, Yuan JM, Anderson KC, Pollak M, Rifai N, et al. Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 120: 4929-37. PMID 23074271 DOI: 10.1182/Blood-2012-03-417253 |
0.354 |
|
| 2012 |
Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH, Venkateswaran V. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer and Prostatic Diseases. 15: 346-52. PMID 22614062 DOI: 10.1038/Pcan.2012.16 |
0.348 |
|
| 2012 |
Jenkins CR, Shevchuk OO, Giambra V, Lam SH, Carboni JM, Gottardis MM, Holzenberger M, Pollak M, Humphries RK, Weng AP. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. Experimental Hematology. 40: 715-723.e6. PMID 22613471 DOI: 10.1016/J.Exphem.2012.05.003 |
0.339 |
|
| 2012 |
Larsson O, Morita M, Topisirovic I, Alain T, Blouin MJ, Pollak M, Sonenberg N. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proceedings of the National Academy of Sciences of the United States of America. 109: 8977-82. PMID 22611195 DOI: 10.1073/Pnas.1201689109 |
0.328 |
|
| 2012 |
Jones LW, Antonelli J, Masko EM, Broadwater G, Lascola CD, Fels D, Dewhirst MW, Dyck JR, Nagendran J, Flores CT, Betof AS, Nelson ER, Pollak M, Dash RC, Young ME, et al. Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. Journal of Applied Physiology (Bethesda, Md. : 1985). 113: 263-72. PMID 22604887 DOI: 10.1152/Japplphysiol.01575.2011 |
0.307 |
|
| 2012 |
Rajpathak SN, He M, Sun Q, Kaplan RC, Muzumdar R, Rohan TE, Gunter MJ, Pollak M, Kim M, Pessin JE, Beasley J, Wylie-Rosett J, Hu FB, Strickler HD. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes. 61: 2248-54. PMID 22554827 DOI: 10.2337/Db11-1488 |
0.328 |
|
| 2012 |
Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker A, Pollak M. A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer Clinical Cancer Research. 18: 3407-3413. PMID 22553344 DOI: 10.1158/1078-0432.CCR-12-0482 |
0.303 |
|
| 2012 |
Gunter JH, Lubik AA, McKenzie I, Pollak M, Nelson CC. The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. Advances in Urology. 2012: 248607. PMID 22548055 DOI: 10.1155/2012/248607 |
0.412 |
|
| 2012 |
Pollak M. Metformin and pancreatic cancer: a clue requiring investigation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2723-5. PMID 22465829 DOI: 10.1158/1078-0432.Ccr-12-0694 |
0.353 |
|
| 2012 |
Faupel-Badger JM, Wang Y, Staff AC, Karumanchi SA, Stanczyk FZ, Pollak M, Hoover RN, Troisi R. Maternal and Cord Steroid Sex Hormones, Angiogenic Factors and Insulin-like Growth Factor Axis in African-American Preeclamptic and Uncomplicated Pregnancies Cancer Causes & Control. 23: 779-784. PMID 22418778 DOI: 10.1007/S10552-012-9934-9 |
0.313 |
|
| 2012 |
Ollberding NJ, Cheng I, Wilkens LR, Henderson BE, Pollak MN, Kolonel LN, Le Marchand L. Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: the Multiethnic Cohort study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 810-20. PMID 22354904 DOI: 10.1158/1055-9965.Epi-11-1105 |
0.304 |
|
| 2012 |
Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update Nature Reviews Cancer. 12: 159-169. PMID 22337149 DOI: 10.1038/Nrc3215 |
0.401 |
|
| 2012 |
Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 40-50. PMID 22215905 DOI: 10.1158/1078-0432.Ccr-11-0998 |
0.355 |
|
| 2012 |
Gao Y, Katki H, Graubard B, Pollak M, Martin M, Tao Y, Schoen RE, Church T, Hayes RB, Greene MH, Berndt SI. Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. International Journal of Cancer. Journal International Du Cancer. 131: E105-13. PMID 21932422 DOI: 10.1002/Ijc.26438 |
0.391 |
|
| 2012 |
Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Research and Treatment. 132: 131-42. PMID 21574055 DOI: 10.1007/S10549-011-1529-8 |
0.394 |
|
| 2012 |
Pollak M. Energy balance and cancer risk at the cellular and whole organism level: modification by metformin Bmc Proceedings. 6. DOI: 10.1186/1753-6561-6-S3-O21 |
0.399 |
|
| 2012 |
Joshua AM, Zannella V, Bowes B, Koritzinsky M, Sweet J, Evans A, Trachtenberg J, Jewett M, Finelli A, Fleshner N, Pollak M. Abstract CT-04: A phase II study of neoadjuvant metformin in prostatic carcinoma Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Ct-04 |
0.391 |
|
| 2012 |
Ma J, Giovannucci E, Nguyen PL, Qiu W, Chavarro J, Rosner B, Cook NR, Platz EA, Gaziano JM, Pollak M, Stampfer MJ. Abstract 4501: Energetic risk and prostate cancer-specific and all-cause mortality in two large cohorts of men with localized prostate cancer Cancer Research. 72: 4501-4501. DOI: 10.1158/1538-7445.Am2012-4501 |
0.317 |
|
| 2012 |
Lubik A, Gunter J, Ettinger S, Fazil L, Stylianou N, Hendy S, Adomat H, Hollier B, Gleave M, Pollak M, Herington A, Nelson C. P03-26 Insulin-like Growth Factor-II increases de novo steroidogenesis in prostate cancer cells Growth Hormone & Igf Research. 22: S80. DOI: 10.1016/S1096-6374(12)60211-1 |
0.431 |
|
| 2012 |
Blouin M, Zhao Y, Birman E, Pollak M. 636 Elevated Insulin Can Reduce Effectiveness of PI3K Inhibitors –Rationale for Co-targeting the Insulin Receptor Family and PI3K European Journal of Cancer. 48: S151. DOI: 10.1016/S0959-8049(12)71284-4 |
0.338 |
|
| 2012 |
Rothermundt CA, Cathomas R, Templeton A, Winterhalder RC, Strebel R, Baertschi D, Pollak M, Lui L, Crowe S, Gillessen S. Metformin in Chemotherapy-Naïve Castration Resistant Prostate Cancer (CRPC): A Multicenter Phase II Trial (SAKK 08/09) Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33475-X |
0.406 |
|
| 2011 |
Segal ED, Yasmeen A, Beauchamp MC, Rosenblatt J, Pollak M, Gotlieb WH. Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochemical and Biophysical Research Communications. 414: 694-9. PMID 21986525 DOI: 10.1016/J.Bbrc.2011.09.134 |
0.303 |
|
| 2011 |
Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci E, Stampfer MJ, Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 2618-27. PMID 21960694 DOI: 10.1158/1055-9965.Epi-11-0434 |
0.386 |
|
| 2011 |
Faupel-Badger JM, Wang Y, Karumanchi SA, Stanczyk F, Pollak M, McElrath T, Hoover RN, Troisi R. Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. Cancer Causes & Control. 22: 1587-1595. PMID 21947778 DOI: 10.1007/S10552-011-9835-3 |
0.341 |
|
| 2011 |
Dool CJ, Mashhedi H, Zakikhani M, David S, Zhao Y, Birman E, Carboni JM, Gottardis M, Blouin MJ, Pollak M. IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Endocrine-Related Cancer. 18: 699-709. PMID 21946410 DOI: 10.1530/Erc-11-0136 |
0.43 |
|
| 2011 |
Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, ... Pollak MN, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3869-76. PMID 21911723 DOI: 10.1200/JCO.2010.33.7006 |
0.334 |
|
| 2011 |
Zhang X, Giovannucci EL, Smith-Warner SA, Wu K, Fuchs CS, Pollak M, Willett WC, Ma J. A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women. Cancer Causes & Control : Ccc. 22: 1627-37. PMID 21909950 DOI: 10.1007/S10552-011-9839-Z |
0.338 |
|
| 2011 |
Mashhedi H, Blouin MJ, Zakikhani M, David S, Zhao Y, Bazile M, Birman E, Algire C, Aliaga A, Bedell BJ, Pollak M. Metformin abolishes increased tumor (18)F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet. Cell Cycle (Georgetown, Tex.). 10: 2770-8. PMID 21811094 DOI: 10.4161/Cc.10.16.16219 |
0.342 |
|
| 2011 |
Medyouf H, Gusscott S, Wang H, Tseng JC, Wai C, Nemirovsky O, Trumpp A, Pflumio F, Carboni J, Gottardis M, Pollak M, Kung AL, Aster JC, Holzenberger M, Weng AP. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. The Journal of Experimental Medicine. 208: 1809-22. PMID 21807868 DOI: 10.1084/Jem.20110121 |
0.308 |
|
| 2011 |
Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, Herington A, Gleave ME, Pollak M, Nelson CC. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Research. 71: 5754-64. PMID 21747118 DOI: 10.1158/0008-5472.Can-10-2470 |
0.43 |
|
| 2011 |
Suissa S, Azoulay L, Dell’Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer Diabetologia. 54: 2254-2262. PMID 21614572 DOI: 10.1007/S00125-011-2190-9 |
0.399 |
|
| 2011 |
Mireuta M, Hancock MA, Pollak M. Binding between insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 is not influenced by glucose or 2-deoxy-D-glucose. The Journal of Biological Chemistry. 286: 16567-73. PMID 21388950 DOI: 10.1074/Jbc.M110.213033 |
0.385 |
|
| 2011 |
Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecologic Oncology. 121: 492-8. PMID 21388661 DOI: 10.1016/J.Ygyno.2011.02.021 |
0.321 |
|
| 2011 |
Tognon CE, Somasiri AM, Evdokimova VE, Trigo G, Uy EE, Melnyk N, Carboni JM, Gottardis MM, Roskelley CD, Pollak M, Sorensen PH. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Cancer Research. 71: 1060-70. PMID 21148487 DOI: 10.1158/0008-5472.Can-10-3096 |
0.421 |
|
| 2011 |
Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene. 30: 1174-1182. PMID 21102522 DOI: 10.1038/Onc.2010.483 |
0.35 |
|
| 2011 |
Takahara K, Tearle H, Ghaffari M, Gleave ME, Pollak M, Cox ME. Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression Prostate. 71: 525-537. PMID 20878948 DOI: 10.1002/Pros.21268 |
0.407 |
|
| 2011 |
Nimptsch K, Platz EA, Pollak MN, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. International Journal of Cancer. Journal International Du Cancer. 128: 660-7. PMID 20473871 DOI: 10.1002/Ijc.25381 |
0.31 |
|
| 2011 |
Ibuki N, Takahara K, Tearle H, Gleave ME, Ong CJ, Pollak M, Cox ME. Abstract 1096: Prostate tumor growth in pbARR2-Cre PTEN knockout mice is delayed in GH/IGF-I deficient mice Cancer Research. 71: 1096-1096. DOI: 10.1158/1538-7445.Am2011-1096 |
0.399 |
|
| 2011 |
Dong B, Chapman J, Yerushalmi R, Goss P, Pollak M, Burnell M, Bramwell V, Levine M, Pritchard K, Whelan T, Ingle J, Parulekar W, Shepherd L, Gelmon K. P5-14-01: Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P5-14-01 |
0.308 |
|
| 2011 |
Bramwell V, Tuck A, Chapman J, Anborgh P, Postenka C, Shepherd L, Pritchard K, Han L, Wilson C, Pollak M, Chambers A. P2-12-28: Studies of a Malignancy-Associated Protein, Osteopontin, in NCIC CTG MA.14, a Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR in Adjuvant Treatment of Women with Early Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-12-28 |
0.306 |
|
| 2011 |
Pollak M. MS3-3: Energy Metabolism in Breast Cancer: Translational Science Insights Relevant to Effects of Diet, Exercise, and Metformin on Risk and Prognosis. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ms3-3 |
0.448 |
|
| 2011 |
Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Fleshner NE, Pollak M, Klotz LH, Venkateswaran V. 936 Utilising Metformin As A Radiosensitising Agent In The Treatment Of Prostate Cancer European Urology Supplements. 10: 293. DOI: 10.1016/S1569-9056(11)60918-4 |
0.335 |
|
| 2011 |
Inoue T, Zakikhani M, Mireuta M, Blouin M, Pollak M. 420 In Vivo Castration-Resistant Acceleration Of Prostate Cancer Inhibited By A Small Molecule Inhibitor Of Insulin-Like Growth Factor 1 Receptor/Insulin Receptor Tyrosine Kinase The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.509 |
0.384 |
|
| 2011 |
Takahara K, Ibuki N, Tearle H, Azuma H, Katsuoka Y, Gleave ME, Ong CJ, Pollak M, Cox ME. 740 Prostate Tumor Growth In Pbarr2-Cre Pten Knockout Mice Is Delayed In Gh/Igf-I Deficient Mice The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1709 |
0.302 |
|
| 2011 |
Colquhoun A, Venier N, Vandersluis A, Fleshner N, Pollak M, Klotz L, Venkateswaran V. 737 Utilizing Metformin As A Radiosensitizing Agent In The Treatment Of Prostate Cancer The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1706 |
0.334 |
|
| 2010 |
Schairer C, McCarty CA, Isaacs C, Sue LY, Pollak MN, Berg CD, Ziegler RG. Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort. Hormones & Cancer. 1: 100-11. PMID 21761353 DOI: 10.1007/s12672-010-0013-y |
0.356 |
|
| 2010 |
Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, Sun P, Narod SA. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer. 117: 1812-8. PMID 21509758 DOI: 10.1002/Cncr.25595 |
0.336 |
|
| 2010 |
Grimaldi-Bensouda L, Marty M, Pollak M, Cameron D, Riddle M, Charbonnel B, Barnett AH, Boffetta P, Boivin JF, Evans M, Rossignol M, Benichou J, Abenhaim L. The international study of insulin and cancer. Lancet (London, England). 376: 769-70. PMID 20816540 DOI: 10.1016/S0140-6736(10)61374-8 |
0.408 |
|
| 2010 |
Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prevention Research (Philadelphia, Pa.). 3: 1060-5. PMID 20810670 DOI: 10.1158/1940-6207.Capr-10-0175 |
0.323 |
|
| 2010 |
Thomas JA, Antonelli JA, Lloyd JC, Masko EM, Poulton SH, Phillips TE, Pollak M, Freedland SJ. Effect of intermittent fasting on prostate cancer tumor growth in a mouse model Prostate Cancer and Prostatic Diseases. 13: 350-355. PMID 20733612 DOI: 10.1038/Pcan.2010.24 |
0.392 |
|
| 2010 |
Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 2298-306. PMID 20699371 DOI: 10.1158/1055-9965.Epi-10-0400 |
0.326 |
|
| 2010 |
Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F, Sonenberg N. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proceedings of the National Academy of Sciences of the United States of America. 107: 14134-9. PMID 20679199 DOI: 10.1073/Pnas.1005320107 |
0.371 |
|
| 2010 |
Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes Diabetologia. 53: 2086-2088. PMID 20645073 DOI: 10.1007/S00125-010-1855-0 |
0.421 |
|
| 2010 |
Canzian F, Cox DG, Setiawan VW, Stram DO, Ziegler RG, Dossus L, Beckmann L, Blanché H, Barricarte A, Berg CD, Bingham S, Buring J, Buys SS, Calle EE, Chanock SJ, ... ... Pollak M, et al. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Human Molecular Genetics. 19: 3873-84. PMID 20634197 DOI: 10.1093/Hmg/Ddq291 |
0.427 |
|
| 2010 |
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 33: 1674-85. PMID 20587728 DOI: 10.2337/Dc10-0666 |
0.351 |
|
| 2010 |
Hou M, Venier N, Sugar L, Musquera M, Pollak M, Kiss A, Fleshner N, Klotz L, Venkateswaran V. Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. Biochemical and Biophysical Research Communications. 397: 537-42. PMID 20573602 DOI: 10.1016/J.Bbrc.2010.05.152 |
0.352 |
|
| 2010 |
Inoue T, Zakikhani M, David S, Algire C, Blouin MJ, Pollak M. Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man. The Prostate. 70: 1628-35. PMID 20564323 DOI: 10.1002/Pros.21198 |
0.396 |
|
| 2010 |
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Ca: a Cancer Journal For Clinicians. 60: 207-21. PMID 20554718 DOI: 10.3322/Caac.20078 |
0.32 |
|
| 2010 |
Pollak M. Beyond steroid hormones: the new cancer endocrinology. Lancet Oncology. 11: 501-502. PMID 20472502 DOI: 10.1016/S1470-2045(10)70116-9 |
0.354 |
|
| 2010 |
Mireuta M, Darnel A, Pollak M. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors Journal. 28: 243-255. PMID 20370577 DOI: 10.3109/08977191003745472 |
0.341 |
|
| 2010 |
Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase Endocrine-Related Cancer. 17: 351-360. PMID 20228137 DOI: 10.1677/Erc-09-0252 |
0.364 |
|
| 2010 |
Pollak M, Russell-Jones D. Insulin analogues and cancer risk: cause for concern or cause célèbre? International Journal of Clinical Practice. 64: 628-36. PMID 20201993 DOI: 10.1111/j.1742-1241.2010.02354.x |
0.319 |
|
| 2010 |
Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL, Pollak M. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prevention Research (Philadelphia, Pa.). 3: 279-89. PMID 20179296 DOI: 10.1158/1940-6207.Capr-09-0188 |
0.371 |
|
| 2010 |
Mucci LA, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ, Ma J. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 484-91. PMID 20142246 DOI: 10.1158/1055-9965.EPI-09-0836 |
0.32 |
|
| 2010 |
Flaig TW, Glodé M, Gustafson D, Van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer Prostate. 70: 848-855. PMID 20127732 DOI: 10.1002/Pros.21118 |
0.323 |
|
| 2010 |
Khalid S, Hwang D, Babichev Y, Kolli R, Altamentova S, Koren S, Goodwin PJ, Ennis M, Pollak M, Sonenberg N, Fantus IG. Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Research and Treatment. 122: 647-59. PMID 19851863 DOI: 10.1007/S10549-009-0586-8 |
0.337 |
|
| 2010 |
Blouin MJ, Zhao Y, Zakikhani M, Algire C, Piura E, Pollak M. Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. Cancer Letters. 289: 246-53. PMID 19744772 DOI: 10.1016/J.Canlet.2009.08.021 |
0.307 |
|
| 2010 |
Medyouf H, Gusscott S, Wai C, Nemirovsky O, Giambra V, Carboni JM, Gottardis M, Pflumio F, Pollak M, Holzenberger M, Weng AP. High-Level IGF1R Expression Is Required for Leukemia Stem Cell Activity In T-ALL and Is Supported by Notch Signaling. Blood. 116: 3649-3649. DOI: 10.1182/Blood.V116.21.3649.3649 |
0.308 |
|
| 2010 |
Wu K, Feskanich D, Fuchs C, Chan A, Willett W, Hollis B, Pollak M, Giovannucci E. Abstract PR-04: Interactions between plasma levels of 25-hydroxyvitamin D and insulin-like growth factor (IGF)-1, IGF-binding proteins and C-peptide with risk of colorectal cancer Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-Pr-04 |
0.378 |
|
| 2010 |
Nimptsch K, Platz E, Pollak M, Willett W, Giovannucci E. Abstract B115: Plasma insulin‐like growth factor 1, binding protein‐3, and risk of prostate cancer: An update from the Health Professional Follow‐up Study 1993–2004 Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-B115 |
0.388 |
|
| 2010 |
Algire C, Amrein L, Bazile M, Zakikhani M, David S, Pollak M. Abstract 65: Metformin inhibits in vivo growth of MC38 colon carcinoma in the absence of LKB1 expression Cancer Research. 70: 65-65. DOI: 10.1158/1538-7445.Am10-65 |
0.35 |
|
| 2010 |
Potratz J, Saunders D, Wai D, Reynolds CP, Buckley JD, Arceci RJ, Reaman GH, Triche TJ, Jürgens H, Pollak M, Sorensen PH. Abstract 3422: Synthetic lethal siRNA screening reveals novel modifiers of insulin-like growth factor-1 receptor (IGF1R) inhibitor activity in childhood sarcomas Cancer Research. 70: 3422-3422. DOI: 10.1158/1538-7445.Am10-3422 |
0.354 |
|
| 2010 |
Colquhoun AJ, Venier NA, Fleshner NE, Pollak M, Klotz LH, Venkateswaran V. Abstract 1799: Utilizing metformin to enhance the efficacy of androgen deprivation therapy in the treatment of prostate cancer Cancer Research. 70: 1799-1799. DOI: 10.1158/1538-7445.Am10-1799 |
0.413 |
|
| 2010 |
Ali S, Aguilar-Mahecha A, Chapman J, Lipton A, Leitzel K, Jahan K, Hassan S, Shepherd L, Han L, Wilson C, Pritchard K, Pollak M, Basik M. Abstract P4-09-09: Serum SDF-1: Biomarker of Bone Relapse in the NCIC MA.14 Adjuvant Breast Cancer Trial Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P4-09-09 |
0.306 |
|
| 2010 |
Colquhoun A, Venier N, Fleshner N, Pollak M, Klotz L, Venkateswaran V. 99 Utilizing Metformin To Enhance The Efficacy Of Androgen Deprivation Therapy In The Treatment Of Prostate Cancer The Journal of Urology. 185: 219. DOI: 10.1016/J.Juro.2010.02.148 |
0.369 |
|
| 2010 |
Antonelli J, Jones L, Thomas J, Masko E, Lloyd J, Poulton S, Phillips T, Tewari A, Febbo P, Pollak M, Dewhirst M, Freedland SJ. 89 Effect Of Voluntary Wheel Running On Growth Of Prostate Cancer In Immunocompromised And Immunocompetent Mouse Models The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.138 |
0.369 |
|
| 2010 |
Hou M, Venier N, Sugar L, Musquera M, Pollak M, Fleshner N, Klotz L, Venkateswaran V. 1434 Role Of Metformin In Prostate Cancer Progression: Mechanistic Studies In A Xenograft Model The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1127 |
0.346 |
|
| 2009 |
Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Current Drug Targets. 10: 923-936. PMID 19663769 DOI: 10.2174/138945009789577945 |
0.43 |
|
| 2009 |
Pollak M. Macronutrient intake and cancer: how does dietary restriction influence tumor growth and why should we care? Cancer Prevention Research (Philadelphia, Pa.). 2: 698-701. PMID 19654107 DOI: 10.1158/1940-6207.Capr-09-0134 |
0.351 |
|
| 2009 |
Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene. 28: 3009-3021. PMID 19581933 DOI: 10.1038/Onc.2009.172 |
0.384 |
|
| 2009 |
Dowling RJ, Pollak M, Sonenberg N. Current status and challenges associated with targeting mTOR for cancer therapy. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 23: 77-91. PMID 19489650 DOI: 10.2165/00063030-200923020-00002 |
0.375 |
|
| 2009 |
Mavropoulos JC, Buschemeyer WC, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV, Freedland SJ. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prevention Research (Philadelphia, Pa.). 2: 557-65. PMID 19470786 DOI: 10.1158/1940-6207.Capr-08-0188 |
0.396 |
|
| 2009 |
Pollak M. Do cancer cells care if their host is hungry? Cell Metabolism. 9: 401-3. PMID 19416708 DOI: 10.1016/J.Cmet.2009.04.006 |
0.407 |
|
| 2009 |
Pollak M. Aging, IGF-1, and diet Aging Cell. 8: 214-214. PMID 19281498 DOI: 10.1111/J.1474-9726.2009.00450.X |
0.38 |
|
| 2009 |
Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N. Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma Cancer Research. 69: 2443-2452. PMID 19258511 DOI: 10.1158/0008-5472.Can-08-2645 |
0.395 |
|
| 2009 |
Pollak M. Energy metabolism, cancer risk, and cancer prevention. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 181: 51-4. PMID 19213556 DOI: 10.1007/978-3-540-69297-3_5 |
0.365 |
|
| 2009 |
Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M. Insulin receptor expression by human prostate cancers. The Prostate. 69: 33-40. PMID 18785179 DOI: 10.1002/Pros.20852 |
0.393 |
|
| 2009 |
Ali S, Chapman J, Lipton A, Leitzel K, Pritchard K, Pu X, Wilson C, Carney W, Shepherd L, Pollak M. Examination of TIMP-1 Levels and Relapse-Free Survival for Patients in NCIC CTG MA.14 Who Received Adjuvant Tamoxifen +/- Octreotide LAR. Cancer Research. 69: 3022-3022. DOI: 10.1158/0008-5472.Sabcs-09-3022 |
0.307 |
|
| 2009 |
Pollak M. Erratum: Insulin and insulin-like growth factor signalling in neoplasia (Erratum) Nature Reviews Cancer. 9: 224-224. DOI: 10.1038/Nrc2605 |
0.427 |
|
| 2009 |
Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Pollak M, Wood L, Winquist E. CUOG PHASE II RANDOMIZED STUDY OF CUSTIRSEN (OGX-011) COMBINATION THERAPY IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER (CRPC) WHO RELAPSED ON OR WITHIN SIX MONTHS OF 1ST-LINE DOCETAXEL THERAPY Journal of Urology. 181: 229-230. DOI: 10.1016/S0022-5347(09)60654-6 |
0.303 |
|
| 2009 |
Freedland SJ, Mavropoulos JC, Buschemeyer WC, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV. A NO CARBOHYDRATE DIET SIGNIFICANTLY PROLONGS SURVIVAL IN A PROSTATE CANCER XENOGRAFT MODEL VIA IGF-1 AND GLOBAL GENE EXPRESSION CHANGES Journal of Urology. 181: 47-47. DOI: 10.1016/S0022-5347(09)60144-0 |
0.354 |
|
| 2008 |
Pollak MN, Chapman JW, Pritchard KI, Krook JE, Dhaliwal HS, Vandenberg TA, Norris BD, Whelan TJ, Wilson CF, Shepherd LE. NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 532. PMID 27948402 DOI: 10.1200/jco.2008.26.15_suppl.532 |
0.303 |
|
| 2008 |
Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Research. 68: 10238-46. PMID 19074892 DOI: 10.1158/0008-5472.Can-08-2755 |
0.424 |
|
| 2008 |
Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 8263-9. PMID 19073970 DOI: 10.1158/1078-0432.Ccr-08-0480 |
0.426 |
|
| 2008 |
Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 176-85. PMID 19064975 DOI: 10.1200/JCO.2008.17.9945 |
0.324 |
|
| 2008 |
Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer. 8: 915-928. PMID 19029956 DOI: 10.1038/Nrc2536 |
0.432 |
|
| 2008 |
So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, Pollak M. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6944-54. PMID 18980989 DOI: 10.1158/1078-0432.Ccr-08-0408 |
0.45 |
|
| 2008 |
Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Practice & Research Clinical Endocrinology & Metabolism. 22: 625-638. PMID 18971123 DOI: 10.1016/J.Beem.2008.08.004 |
0.457 |
|
| 2008 |
Chitnis MM, Yuen JSP, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clinical Cancer Research. 14: 6364-6370. PMID 18927274 DOI: 10.1158/1078-0432.Ccr-07-4879 |
0.397 |
|
| 2008 |
Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Research : Bcr. 10: R86. PMID 18925950 DOI: 10.1186/Bcr2156 |
0.376 |
|
| 2008 |
Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV, Helzlsouer K, Rinaldi S, Riboli E, ... ... Pollak M, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Annals of Internal Medicine. 149: 461-71, W83-8. PMID 18838726 DOI: 10.7326/0003-4819-149-7-200810070-00006 |
0.435 |
|
| 2008 |
Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. The Lancet. Oncology. 9: 1039-47. PMID 18835745 DOI: 10.1016/S1470-2045(08)70235-3 |
0.339 |
|
| 2008 |
Stolzenberg-Solomon RZ, Weinstein S, Pollak M, Tao Y, Taylor PR, Virtamo J, Albanes D. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. American Journal of Epidemiology. 168: 1047-55. PMID 18801887 DOI: 10.1093/Aje/Kwn221 |
0.357 |
|
| 2008 |
Diorio C, Sinotte M, Brisson J, Bérubé S, Pollak M. Vitamin D pathway polymorphisms in relation to mammographic breast density. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 2505-8. PMID 18768522 DOI: 10.1158/1055-9965.Epi-08-0493 |
0.326 |
|
| 2008 |
Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Current Opinion in Pharmacology. 8: 384-92. PMID 18674638 DOI: 10.1016/J.Coph.2008.07.004 |
0.362 |
|
| 2008 |
Max JB, Limburg PJ, Ogunseitan A, Stolzenberg-Solomon RZ, Vierkant RA, Pollak MJ, Sellers TA, Virtamo J, Cerhan JR, Albanes D. IGF-I, IGFBP-3, and IGF-I/IGFBP-3 ratio: No association with incident colorectal cancer in the alpha-tocopherol, beta-carotene cancer prevention study Cancer Epidemiology, Biomarkers & Prevention. 17: 1832-1834. PMID 18628438 DOI: 10.1158/1055-9965.Epi-08-0345 |
0.309 |
|
| 2008 |
Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. The Prostate. 68: 1477-86. PMID 18618736 DOI: 10.1002/Pros.20819 |
0.401 |
|
| 2008 |
Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossus L, Haiman CA, Hankinson SE, ... ... Pollak M, et al. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). Plos One. 3: e2578. PMID 18596909 DOI: 10.1371/Journal.Pone.0002578 |
0.44 |
|
| 2008 |
Diorio C, Brisson J, Bérubé S, Pollak M. Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional study. Breast Cancer Research : Bcr. 10: R42. PMID 18471292 DOI: 10.1186/Bcr2093 |
0.439 |
|
| 2008 |
Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocrine-Related Cancer. 15: 833-9. PMID 18469156 DOI: 10.1677/Erc-08-0038 |
0.32 |
|
| 2008 |
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GYF, Einstein MH, Kaplan RC, Burk RD, Wylie-Rosett J, Pollak MN, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer Cancer Epidemiology Biomarkers and Prevention. 17: 921-929. PMID 18398032 DOI: 10.1158/1055-9965.Epi-07-2686 |
0.315 |
|
| 2008 |
Diorio C, Brisson J, Bérubé S, Pollak M. Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 880-8. PMID 18398029 DOI: 10.1158/1055-9965.Epi-07-2500 |
0.403 |
|
| 2008 |
Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak MD, Whittemore AS, Wu AH, Gallagher RP. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 252-4. PMID 18199733 DOI: 10.1158/1055-9965.Epi-07-2694 |
0.34 |
|
| 2008 |
Rajpathak SN, McGinn AP, Strickler HD, Rohan TE, Pollak M, Cappola AR, Kuller L, Xue X, Newman AB, Strotmeyer ES, Psaty BM, Kaplan RC. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Hormone & Igf Research : Official Journal of the Growth Hormone Research Society and the International Igf Research Society. 18: 166-73. PMID 17904401 DOI: 10.1016/J.Ghir.2007.08.004 |
0.339 |
|
| 2007 |
Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. Journal of the National Cancer Institute. 99: 1793-800. PMID 18042933 DOI: 10.1093/Jnci/Djm231 |
0.359 |
|
| 2007 |
Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research. 67: 10804-12. PMID 18006825 DOI: 10.1158/0008-5472.Can-07-2310 |
0.363 |
|
| 2007 |
Tworoger SS, Lee IM, Buring JE, Pollak MN, Hankinson SE. Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 1691-5. PMID 17684148 DOI: 10.1158/1055-9965.EPI-07-0319 |
0.303 |
|
| 2007 |
Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J. Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. The Prostate. 67: 1354-61. PMID 17624927 DOI: 10.1002/Pros.20589 |
0.39 |
|
| 2007 |
Levitt RJ, Zhao Y, Blouin MJ, Pollak M. The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer Letters. 255: 300-6. PMID 17602833 DOI: 10.1016/J.Canlet.2007.05.006 |
0.382 |
|
| 2007 |
Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak MN, Fuchs CS. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts British Journal of Cancer. 97: 98-104. PMID 17533398 DOI: 10.1038/Sj.Bjc.6603826 |
0.317 |
|
| 2007 |
Lönn S, Inskip PD, Pollak MN, Weinstein SJ, Virtamo J, Albanes D. Glioma risk in relation to serum levels of insulin-like growth factors. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 844-6. PMID 17416782 DOI: 10.1158/1055-9965.EPI-06-1010 |
0.314 |
|
| 2007 |
McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstetrics and Gynecology. 109: 933-41. PMID 17400857 DOI: 10.1097/01.Aog.0000257126.68803.03 |
0.325 |
|
| 2007 |
Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 174: 49-53. PMID 17302184 DOI: 10.1007/978-3-540-37696-5_4 |
0.439 |
|
| 2007 |
de Bono JS, Adjei A, Attard G, Pollak M, Fong P, Haluska P, Roberts L, Chainese D, Terstappen L, Gualberto A. Circulating tumor cells expressing the insulin growth factor-1 receptor (IGF-1R): Method of detection, incidence and potential applications Journal of Clinical Oncology. 25: 3507-3507. DOI: 10.1200/Jco.2007.25.18_Suppl.3507 |
0.347 |
|
| 2007 |
Lacy MQ, Alsina M, Roberts L, Fonseca R, Melvin C, Yin D, Sharma A, Pollak M, Jagannath S, Richardson P, Gualberto A. Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma. Blood. 110: 1171-1171. DOI: 10.1182/Blood.V110.11.1171.1171 |
0.317 |
|
| 2006 |
Tran CD, Diorio C, Bérubé S, Pollak M, Brisson J. Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. The American Journal of Clinical Nutrition. 84: 1518-26. PMID 17158438 DOI: 10.1093/Ajcn/84.6.1518 |
0.335 |
|
| 2006 |
Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research. 66: 10269-73. PMID 17062558 DOI: 10.1158/0008-5472.Can-06-1500 |
0.438 |
|
| 2006 |
Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Molecular Pharmacology. 70: 1534-41. PMID 16887935 DOI: 10.1124/Mol.106.023911 |
0.399 |
|
| 2006 |
Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocrine-Related Cancer. 13: 583-92. PMID 16728584 DOI: 10.1677/ERC.1.01149 |
0.316 |
|
| 2006 |
Diorio C, Bérubé S, Byrne C, Mâsse B, Hébert-Croteau N, Yaffe M, Coté G, Pollak M, Brisson J. Influence of insulin-like growth factors on the strength of the relation of vitamin D and calcium intakes to mammographic breast density. Cancer Research. 66: 588-97. PMID 16397276 DOI: 10.1158/0008-5472.Can-05-1959 |
0.357 |
|
| 2006 |
Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y, Pollak MN. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecologic Oncology. 100: 389-96. PMID 16300820 DOI: 10.1016/j.ygyno.2005.09.048 |
0.322 |
|
| 2006 |
Rollison DE, Newschaffer CJ, Tao Y, Pollak M, Helzlsouer KJ. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. International Journal of Cancer. Journal International Du Cancer. 118: 1279-84. PMID 16161053 DOI: 10.1002/Ijc.21471 |
0.423 |
|
| 2006 |
Rich-Edwards J, Ganmaa D, Pollak M, Nakamoto E, Willett W, Frazier L. Bioactive Factors in Cow's Milk Raise Levels of Growth Hormone and insulin-Like Growth Factor I in Prepubertal Girls American Journal of Epidemiology. 163: S103-S103. DOI: 10.1093/Aje/163.Suppl_11.S103-A |
0.367 |
|
| 2005 |
So AI, Eigl B, Fazli L, Hunstman D, Ivanonv N, Pollak M, Dunn S, Gleave M. Significance of insulin-like growth factor binding protein-2 in the prognosis of breast cancer and promotion of accelerated growth and chemo-resistance in MDAMB-231 breast cancer model. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 542. PMID 27946431 DOI: 10.1200/Jco.2005.23.16_Suppl.542 |
0.449 |
|
| 2005 |
Diorio C, Pollak M, Byrne C, Mâsse B, Hébert-Croteau N, Yaffe M, Coté G, Bérubé S, Brisson J. Levels of C-peptide and mammographic breast density. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 2661-4. PMID 16284393 DOI: 10.1158/1055-9965.Epi-05-0466 |
0.345 |
|
| 2005 |
Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Research : Bcr. 7: R796-807. PMID 16168126 DOI: 10.1186/Bcr1294 |
0.408 |
|
| 2005 |
Levitt RJ, Georgescu MM, Pollak M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochemical and Biophysical Research Communications. 336: 1056-61. PMID 16154532 DOI: 10.1016/J.Bbrc.2005.08.229 |
0.391 |
|
| 2005 |
Bérubé S, Diorio C, Mâsse B, Hébert-Croteau N, Byrne C, Côté G, Pollak M, Yaffe M, Brisson J. Vitamin D and calcium intakes from food or supplements and mammographic breast density. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1653-9. PMID 16030097 DOI: 10.1158/1055-9965.Epi-05-0068 |
0.31 |
|
| 2005 |
Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Research : Bcr. 7: R570-9. PMID 15987464 DOI: 10.1186/Bcr1028 |
0.432 |
|
| 2005 |
Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era Cancer Causes and Control. 16: 255-262. PMID 15947877 DOI: 10.1007/S10552-004-3484-8 |
0.312 |
|
| 2005 |
Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson SK, Findlay BP, Fuchs CS. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1402-10. PMID 15941948 DOI: 10.1158/1055-9965.Epi-04-0862 |
0.392 |
|
| 2005 |
Nam RK, Trachtenberg J, Jewett MA, Toi A, Evans A, Emami M, Narod SA, Pollak M. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1270-3. PMID 15894684 DOI: 10.1158/1055-9965.Epi-04-0430 |
0.387 |
|
| 2005 |
Diorio C, Pollak M, Byrne C, Mâsse B, Hébert-Croteau N, Yaffe M, Coté G, Bérubé S, Morin C, Brisson J. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1065-73. PMID 15894654 DOI: 10.1158/1055-9965.Epi-04-0706 |
0.374 |
|
| 2005 |
Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak M. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene. 24: 4736-40. PMID 15870705 DOI: 10.1038/Sj.Onc.1208572 |
0.396 |
|
| 2005 |
Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 850-5. PMID 15824155 DOI: 10.1158/1055-9965.EPI-04-0661 |
0.328 |
|
| 2005 |
Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 24: 4281-92. PMID 15806160 DOI: 10.1038/Sj.Onc.1208590 |
0.369 |
|
| 2005 |
Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 699-704. PMID 15767352 DOI: 10.1158/1055-9965.EPI-04-0561 |
0.34 |
|
| 2005 |
Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 455-60. PMID 15659491 DOI: 10.1200/Jco.2005.02.129 |
0.374 |
|
| 2005 |
Pollak M. Individualizing interventions for cancer prevention. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 166: 63-9. PMID 15648183 DOI: 10.1007/3-540-26980-0_5 |
0.302 |
|
| 2004 |
Pollak MN. Insulin-like growth factors and neoplasia. Novartis Foundation Symposium. 262: 84-98; discussion 98. PMID 15562824 |
0.356 |
|
| 2004 |
Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. British Journal of Cancer. 90: 1825-9. PMID 15150607 DOI: 10.1038/Sj.Bjc.6601682 |
0.357 |
|
| 2004 |
Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, Stampfer MJ. A prospective study of plasma C-peptide and colorectal cancer risk in men. Journal of the National Cancer Institute. 96: 546-553. PMID 15069117 DOI: 10.1093/Jnci/Djh082 |
0.392 |
|
| 2004 |
Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ, Pollak M. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochemical and Biophysical Research Communications. 316: 421-8. PMID 15020235 DOI: 10.1016/J.Bbrc.2004.02.062 |
0.437 |
|
| 2004 |
Stolzenberg-Solomon RZ, Limburg P, Pollak M, Taylor PR, Virtamo J, Albanes D. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 13: 438-44. PMID 15006921 |
0.311 |
|
| 2004 |
Labrie F, Champagne P, Labrie C, Roy J, Laverdière J, Provencher L, Potvin M, Drolet Y, Pollak M, Panasci L, L'Espérance B, Dufresne J, Latreille J, Robert J, Samson B, et al. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer Journal of Clinical Oncology. 22: 864-871. PMID 14990642 DOI: 10.1200/Jco.2004.05.122 |
0.348 |
|
| 2004 |
Lu Y, Zi X, Zhao Y, Pollak M. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. Biochemical and Biophysical Research Communications. 313: 709-15. PMID 14697248 DOI: 10.1016/J.Bbrc.2003.12.007 |
0.663 |
|
| 2004 |
Schairer C, Hill D, Sturgeon SR, Fears T, Pollak M, Mies C, Ziegler RG, Hoover RN, Sherman ME. Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. International Journal of Cancer. Journal International Du Cancer. 108: 773-9. PMID 14696106 DOI: 10.1002/Ijc.11624 |
0.415 |
|
| 2004 |
Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. International Journal of Cancer. 108: 334-41. PMID 14648698 DOI: 10.1002/Ijc.11445 |
0.662 |
|
| 2003 |
Ismail HA, Pollak M, Behlouli H, Tanguay S, Bégin LR, Aprikian AG. Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. Bju International. 92: 699-702. PMID 14616449 DOI: 10.1046/J.1464-410X.2003.04084.X |
0.433 |
|
| 2003 |
Nomura AM, Stemmermann GN, Lee J, Pollak MN. Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. American Journal of Epidemiology. 158: 424-31. PMID 12936897 DOI: 10.1093/AJE/KWG176 |
0.329 |
|
| 2003 |
Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like growth factor I: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men Cancer Research. 63: 3991-3994. PMID 12873996 |
0.322 |
|
| 2003 |
Limburg P, Vierkant R, Stolzenberg-Solomon R, Sellers T, Pollak M, Virtamo J, Albanes D. Insulin, insulin-like growth factor proteins, and colorectal cancer risk in the ATBC study Gastroenterology. 124. DOI: 10.1016/S0016-5085(03)80387-6 |
0.417 |
|
| 2002 |
Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 8: BR521-6. PMID 12503030 |
0.649 |
|
| 2002 |
Deitel K, Dantzer D, Ferguson P, Pollak M, Beamer W, Andrulis I, Bell R. Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation. Journal of Surgical Oncology. 81: 75-9. PMID 12355407 DOI: 10.1002/Jso.10136 |
0.353 |
|
| 2002 |
Giovannucci E, Pollak M. Risk of cancer after growth-hormone treatment. Lancet (London, England). 360: 268-9. PMID 12147365 DOI: 10.1016/S0140-6736(02)09561-2 |
0.377 |
|
| 2002 |
Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Re: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer Journal of the National Cancer Institute. 94: 1099-1106. PMID 12122101 DOI: 10.1093/Jnci/94.14.1099 |
0.408 |
|
| 2002 |
Pollak M. Insulin-like growth factors and prostate cancer. Epidemiologic Reviews. 23: 59-66. PMID 11588855 DOI: 10.1023/A:1006154108619 |
0.425 |
|
| 2002 |
A HI, Pollak M, Behlouli H, Tanguay S, Bégin LR, Aprikian AG. Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. The Journal of Urology. 168: 2426-2430. DOI: 10.1016/S0022-5347(05)64160-2 |
0.406 |
|
| 2001 |
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). Journal of the National Cancer Institute. 93: 1852-7. PMID 11752009 DOI: 10.1093/Jnci/93.24.1852 |
0.678 |
|
| 2001 |
Tolcher AW, Kennedy A, Padley RJ, Majeed N, Pollak M, Kantoff PW. Other novel agents: Rationale and current status as chemopreventive agents Urology. 57: 86-89. PMID 11295602 DOI: 10.1016/S0090-4295(00)00948-1 |
0.345 |
|
| 2001 |
Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. The Journal of Clinical Endocrinology and Metabolism. 86: 1274-1280. PMID 11238520 DOI: 10.1210/Jcem.86.3.7280 |
0.388 |
|
| 2001 |
Jernström H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M, Narod SA. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Molecular Genetics and Metabolism. 72: 144-54. PMID 11161840 DOI: 10.1006/Mgme.2000.3130 |
0.356 |
|
| 2001 |
Chan JM, Stampfer MJ, Giovannucci E, Ma J, Pollak M. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. Growth Hormone & Igf Research : Official Journal of the Growth Hormone Research Society and the International Igf Research Society. S32-3. PMID 10984284 DOI: 10.1016/S1096-6374(00)90015-7 |
0.439 |
|
| 2001 |
Ma J, Pollak M, Giovannucci E, Chan JM, Tao Y, Hennekens C, Stampfer MJ. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Hormone & Igf Research : Official Journal of the Growth Hormone Research Society and the International Igf Research Society. S28-9. PMID 10984282 DOI: 10.1016/S1096-6374(00)90013-3 |
0.422 |
|
| 2001 |
Byrne C, Hankinson SE, Pollak M, Willett WC, Colditz GA, Speizer FE. Insulin-like growth factors and mammographic density. Growth Hormone & Igf Research : Official Journal of the Growth Hormone Research Society and the International Igf Research Society. S24-5. PMID 10984280 DOI: 10.1016/S1096-6374(00)90011-X |
0.363 |
|
| 2001 |
Pollak M. Insulin-like growth factor physiology and neoplasia. Growth Hormone & Igf Research : Official Journal of the Growth Hormone Research Society and the International Igf Research Society. S6-7. PMID 10984271 DOI: 10.1016/S1096-6374(00)90002-9 |
0.37 |
|
| 2001 |
Pollak M. The question of a link between insulin-like growth factor physiology and neoplasia. Growth Hormone & Igf Research : Official Journal of the Growth Hormone Research Society and the International Igf Research Society. S21-4. PMID 10984249 DOI: 10.1016/S1096-6374(00)80005-2 |
0.426 |
|
| 2001 |
Ma J, Giovannucci E, Pollak M, Chan JM, Gaziano JM, Willett W, Stampfer MJ. Milk Intake, Circulating Levels of Insulin-Like Growth Factor-I, and Risk of Colorectal Cancer in Men Jnci Journal of the National Cancer Institute. 93: 1330-1336. DOI: 10.1093/Jnci/93.17.1330 |
0.415 |
|
| 2000 |
Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, Euler MV. Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial Journal of Clinical Oncology. 18: 3758-3767. PMID 11078488 DOI: 10.1200/Jco.2000.18.22.3758 |
0.319 |
|
| 2000 |
Giovannucci E, Pollak M, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the nurses' health study Growth Hormone and Igf Research. 10. PMID 10984283 DOI: 10.1016/S1096-6374(00)90014-5 |
0.391 |
|
| 2000 |
Pollak M. Insulin-like growth factor physiology and cancer risk. European Journal of Cancer (Oxford, England : 1990). 36: 1224-8. PMID 10882860 DOI: 10.1016/S0959-8049(00)00102-7 |
0.418 |
|
| 2000 |
Wilkin F, Paquette J, Ledru E, Mamelin C, Pollak M, Deal CL. H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. Febs Journal. 267: 4020-4027. PMID 10866801 DOI: 10.1046/J.1432-1327.2000.01438.X |
0.317 |
|
| 2000 |
Huynh H, Beamer W, Pollak M, Chan TWMG. Modulation of transforming growth factor beta1 gene expression in the mammary gland by insulin-like growth factor I and octreotide. International Journal of Oncology. 16: 277-358. PMID 10639570 DOI: 10.3892/Ijo.16.2.277 |
0.323 |
|
| 2000 |
Pollak M, Besser GM, Cohen P, Rosenfeld RG. First International Workshop on Growth Hormone, Insulin-like Growth Factors and Neoplasia Growth Hormone & Igf Research. 10. DOI: 10.1016/S1096-6374(00)90000-5 |
0.367 |
|
| 1999 |
Nickerson T, Pollak M. Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins Urology. 54: 1120-1125. PMID 10604720 DOI: 10.1016/S0090-4295(99)00421-5 |
0.4 |
|
| 1999 |
Rozen F, Pollak M. Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells : A role for insulin-like growth factor binding proteins International Journal of Oncology. 15: 589-683. PMID 10427145 DOI: 10.3892/Ijo.15.3.589 |
0.426 |
|
| 1999 |
Rosen CJ, Pollak M. Circulating IGF-I: New Perspectives for a New Century. Trends in Endocrinology and Metabolism. 10: 136-141. PMID 10322407 DOI: 10.1016/S1043-2760(98)00126-X |
0.396 |
|
| 1999 |
Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. Journal of the National Cancer Institute. 91: 620-5. PMID 10203281 DOI: 10.1093/jnci/91.7.620 |
0.331 |
|
| 1999 |
Nickerson T, Zhang J, Pollak M. Regression of DMBA-induced breast carcinoma following ovariectomy is associated with increased expression of genes encoding insulin-like growth factor binding proteins. International Journal of Oncology. 14: 987-1077. PMID 10200352 DOI: 10.3892/Ijo.14.5.987 |
0.382 |
|
| 1999 |
Pollak M. IGF-I physiology and breast cancer. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 152: 63-70. PMID 9928547 DOI: 10.1007/978-3-642-45769-2_6 |
0.399 |
|
| 1999 |
Toppmeyer D, Seidman A, Overmoyer B, Pollak M, Verma S, Russell C, Tkaczuk K, Prete SD, Schwartz G, Harding MW. A Phase II study of IncelTM (biricodar, VX-710) in combination with paclitaxel in women with advanced breast cancer refractory to paclitaxel European Journal of Cancer. 35. DOI: 10.1016/S0959-8049(99)81708-0 |
0.324 |
|
| 1998 |
Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. Journal of Surgical Oncology. 69: 21-7. PMID 9762887 DOI: 10.1002/(Sici)1096-9098(199809)69:1<21::Aid-Jso5>3.0.Co;2-M |
0.386 |
|
| 1998 |
Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breastcancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. International Journal of Oncology. 13: 865-874. PMID 9735418 DOI: 10.3892/Ijo.13.4.865 |
0.332 |
|
| 1998 |
Huynh H, Pollak M, Zhang JC. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089 International Journal of Oncology. 13: 137-143. PMID 9625815 DOI: 10.3892/Ijo.13.1.137 |
0.426 |
|
| 1998 |
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer Lancet. 351: 1393-1396. PMID 9593409 DOI: 10.1016/S0140-6736(97)10384-1 |
0.412 |
|
| 1998 |
Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Research and Treatment. 47: 209-17. PMID 9516077 DOI: 10.1023/A:1005950916707 |
0.326 |
|
| 1998 |
Nickerson T, Pollak M, Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5 Endocrinology. 139: 807-810. PMID 9449659 DOI: 10.1210/Endo.139.2.5912 |
0.377 |
|
| 1998 |
Chan J, Stampfer M, Giovannucci E, Gann P, Ma J, Wilkinson P, Hennekens C, Pollak M. Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study Journal of Urology. 160: 267-267. DOI: 10.1126/Science.279.5350.563 |
0.406 |
|
| 1998 |
Pollak M. I.4 Effects of anti-oestrogens on insulin-like growth factor (IGF-I) physiology systemically and in the uterus European Journal of Cancer. 34: S11-S12. DOI: 10.1016/S0959-8049(98)00087-2 |
0.402 |
|
| 1998 |
Hankinson SE, Willett WC, Speizer FE, Pollak M. Insulin-like growth factor-l and risk of breast cancer The Lancet. 352: 489. DOI: 10.1016/S0140-6736(05)79228-X |
0.424 |
|
| 1997 |
Huynh H, Beamer WD, Pollak M. Overexpression of insulin-like growth factor binding protein 4 (IGFBP-4) in MCF-7 breast cancer cells is associated with reduced responsiveness to insulin-like growth factors in vitro and reduced tumour growth in vivo. International Journal of Oncology. 11: 193-197. PMID 21528201 DOI: 10.3892/Ijo.11.1.193 |
0.432 |
|
| 1997 |
Nickerson T, Huynh H, Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells Biochemical and Biophysical Research Communications. 237: 690-693. PMID 9299428 DOI: 10.1006/Bbrc.1997.7089 |
0.412 |
|
| 1997 |
Rozen F, Yang X, Huynh H, Pollak M. Antiproliferative Action of Vitamin D-Related Compounds and Insulin-Like Growth Factor-Binding Protein 5 Accumulation Journal of the National Cancer Institute. 89: 652-656. PMID 9150190 DOI: 10.1093/Jnci/89.9.652 |
0.384 |
|
| 1996 |
Pollak M. Enhancement of the Anti-Neoplastic Effects of Tamoxifen by Somatostatin Analogues Digestion. 57: 29-33. PMID 8813463 DOI: 10.1159/000201389 |
0.353 |
|
| 1996 |
Pollak M. Peptide growth factors and breast cancer treatment: recent translational research. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 140: 43-9. PMID 8787075 DOI: 10.1007/978-3-642-79278-6_6 |
0.344 |
|
| 1996 |
Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells Journal of Biological Chemistry. 271: 1016-1021. PMID 8557625 DOI: 10.1074/Jbc.271.2.1016 |
0.421 |
|
| 1995 |
Hung H, Pollak M. Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: Correlations with effects on proliferation: A review Progress in Growth Factor Research. 6: 495-501. PMID 8817694 DOI: 10.1016/0955-2235(95)00036-4 |
0.411 |
|
| 1995 |
Rosenberg L, Barkun AN, Denis MH, Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer. 75: 23-8. PMID 7804972 DOI: 10.1002/1097-0142(19950101)75:1<23::Aid-Cncr2820750106>3.0.Co;2-A |
0.314 |
|
| 1995 |
Pollak M. Re: Reversal by Transferrin of Growth-Inhibitory Effect of Suramin on Hormone-Refractory Human Prostate Cancer Cells Journal of the National Cancer Institute. 87: 608-608. PMID 7752260 DOI: 10.1093/Jnci/87.8.608 |
0.384 |
|
| 1995 |
Pollak M. Re: Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example. Journal of the National Cancer Institute. 87: 1557-1557. PMID 7563192 DOI: 10.1093/Jnci/87.20.1557 |
0.354 |
|
| 1994 |
Sekyi-Otu A, Bell R, Andrulis I, Pollak M. Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement. Journal of the National Cancer Institute. 86: 628-32. PMID 8145278 DOI: 10.1093/Jnci/86.8.628 |
0.362 |
|
| 1994 |
Huynh H, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue Biochemical and Biophysical Research Communications. 203: 253-259. PMID 8074663 DOI: 10.1006/Bbrc.1994.2175 |
0.326 |
|
| 1994 |
Arbour L, Narod S, Glendon G, Pollak M, Seymour R, Miner L, Leung P. In-vitro fertilisation and family history of breast cancer The Lancet. 344: 610-611. PMID 7914975 DOI: 10.1016/S0140-6736(94)91994-1 |
0.324 |
|
| 1993 |
Friedl A, Jordan VC, Pollak M. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. European Journal of Cancer (Oxford, England : 1990). 29: 1368-72. PMID 8398260 DOI: 10.1016/0959-8049(93)90003-X |
0.381 |
|
| 1993 |
Tonin P, Ehrenborg E, Lenoir G, Feunteun J, Lynch H, Morgan K, Zazzi H, Vivier A, Pollak M, Huynh H, Luthman H, Larsson C, Narod S. The Human Insulin-like Growth Factor-Binding Protein 4 Gene Maps to Chromosome Region 17q12-q21.1 and Is Close to the Gene for Hereditary Breast-Ovarian Cancer Genomics. 18: 414-417. PMID 7507078 DOI: 10.1006/Geno.1993.1487 |
0.352 |
|
| 1992 |
Pollak MN, Huynh HT, Lefebvre SP. Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Research and Treatment. 22: 91-100. PMID 1421427 DOI: 10.1007/BF01833337 |
0.317 |
|
| 1992 |
Pollak M, Gallant K, Poisson R, Harris A. Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial. Metabolism-Clinical and Experimental. 41: 119-120. PMID 1355585 DOI: 10.1016/0026-0495(92)90045-C |
0.36 |
|
| 1992 |
Tannenbaum GS, Gurd W, Lapointe M, Pollak M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology. 130: 3395-401. PMID 1350760 DOI: 10.1210/Endo.130.6.1350760 |
0.334 |
|
| 1992 |
Pollak M, Sem AW, Richard M, Tetenes E, Bell R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. Journal of the National Cancer Institute. 84: 966-71. PMID 1321252 DOI: 10.1093/Jnci/84.12.966 |
0.339 |
|
| 1991 |
Pollak M, Boyarsky A, Gora P. A mathematical model describing consequences of abnormally high levels of epidermal growth factor receptor on the proliferation of neoplastic cells. Cancer Investigation. 9: 513-20. PMID 1933484 DOI: 10.3109/07357909109018949 |
0.304 |
|
| 1991 |
Dawson NA, Costanza ME, Korzun AH, Clamon GH, Pollak M, Vogelzang NJ, Carey RW, Norton L. Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. Medical and Pediatric Oncology. 19: 283-8. PMID 1829134 DOI: 10.1002/Mpo.2950190413 |
0.338 |
|
| 1990 |
Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, Fisher B, Margolese R. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients Journal of the National Cancer Institute. 82: 1693-1697. PMID 2231756 DOI: 10.1093/Jnci/82.21.1693 |
0.434 |
|
| 1990 |
Pollak M, Richard M. Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. Journal of the National Cancer Institute. 82: 1349-52. PMID 2166171 DOI: 10.1093/Jnci/82.16.1349 |
0.353 |
|
| Show low-probability matches. |